Upregulation of BIRC5 plays essential role in esophageal squamous cell carcinoma

Chen, Zu-Xuan; Li, Guosheng; Yang, Lihua; Liu, He-Chuan; Qin, Gang; Shen, Lang; He, Wei-Ying; Gan, Ting‐Qing; Li, Jianjun

doi:10.3934/mbe.2021345

Cited by 4 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The experiment was performed following the manufacturer's instructions. The immunohistochemical experimental methods and protein level scoring criteria were consistent with our previous study [ 19 ].…”

Section: Methodssupporting

confidence: 67%

Ogt Demonstrated Conspicuous Clinical Significance in Cancers, from Pan-Cancer to Small-Cell Lung Cancer

Tang

et al. 2022

Journal of Oncology

Self Cite

View full text Add to dashboard Cite

The clinical progression of small-cell lung cancer (SCLC) remains pessimistic. The aim of the present study was to promote the understanding of the clinical significance and mechanism of O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) in SCLC. Wilcoxon tests, standardized mean difference (SMD), and Kruskal–Wallis tests were utilized to compare OGT level differences among the experimental and control groups. The univariate Cox regression analysis, Kaplan–Meier curves, and receiver operating characteristic curves were applied to determine OGT’s clinical relevance in cancers. The Spearman correlation analysis and enrichment analysis were utilized to explore the underlying mechanisms of OGT in cancers. For the first time in the field, we provide an overview of OGT in 32 cancers using a large number of samples (n = 21,196), determining distinct OGT expression in 25 cancers and its prognosis effects in 12 cancers. Furthermore, using 950 samples from multiple sources, upregulated OGT was found in both mRNA and protein levels in SCLC (SMD = 0.93, 95% CI [0.24, 1.63]). Higher OGT levels represented a more unfavorable disease-free interval for SCLC patients ( p < 0.001 ). The research also identified OGT expression as a potential marker for SCLC prediction (sensitivity = 0.79, specificity = 0.86, and AUC = 0.88). The high expression of OGT in SCLC may result from the positive regulation of two transcription factors—DEK and XRN2. We primarily investigated the underlying mechanisms of OGT in SCLC. Herein, based on the analyses from pan-cancer to SCLC, OGT demonstrated conspicuous clinical significance. OGT may be an underlying biomarker for the treatment and identification of some cancers, including SCLC.

show abstract

Section: Methodssupporting

confidence: 67%

Ogt Demonstrated Conspicuous Clinical Significance in Cancers, from Pan-Cancer to Small-Cell Lung Cancer

Tang

et al. 2022

Journal of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cytokines in lymphocytes have been shown to control the expression of BIRC5, which is essential for the growth and survival of hematopoietic cells. In the context of human cancers, BIRC5 has been reported to inhibit cell apoptosis while stimulating cell proliferation (26,27). Previous studies have revealed that BIRC5 exerts its anti-apoptotic effects through the suppression of both caspase-dependent and caspase-independent apoptotic pathways, in addition to promoting cell growth and development.…”

Section: Discussionmentioning

confidence: 99%

BIRC5 expression correlated with immunosuppressive phenotype and predicted inferior response to immunotherapy in lung adenocarcinoma

Yang,

Liu,

Mao

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Considering the pivotal role of BIRC5 in tumorigenesis, recurrence, and chemoresistance, this study aimed to investigate its impact on the clinical and tumor microenvironmental features of lung adenocarcinoma (LUAD), together with its predictive and prognostic values. Methods Clinical and transcriptomic data of 535 LUAD samples, 59 normal lung, and 54 patients with non-small-cell lung cancer (NSCLC) received immune checkpoint blockades (ICB) were analyzed. Deconvolution analysis was conducted to uncover the relationship between tumor microenvironmental features and BIRC5 expression level. The predictive and prognostic values of BIRC5 was also evaluated with Log-rank test and Cox regression analysis. Results LUAD had a significantly higher BIRC5 expression level than normal lung tissues. The elevated BIRC5 expression was markedly associated with unfavorable clinical outcomes. Transcriptomic and single-cell sequencing data analysis revealed that tumors with high BIRC5 expression was correlated with multiple pathways’ enrichment. Deconvolution analysis indicated a negative correlation between BIRC5 expression and infiltration levels of CD8 + T cells, dendritic cells, and NK cells in LUAD, but a positive correlation was observed between BIRC5 expression and regulatory T cells (Tregs) infiltrations. Importantly, NSCLC patients received ICB with high BIRC5 expression had dramatically shorter progression-free (1.2 vs. 4.5 months; P = 0.012) and overall survival (3.1 vs. 12.7 months; P = 0.005) than those with low BIRC5 expression. Conclusions These findings suggested that high BIRC5 expression was associated with DNA damage/repair, cell invasion and proliferation related pathways enrichment and increased Tregs infiltration, which would result in inferior outcomes in NSCLC received ICB.

show abstract

“…Immunohistochemical experiments were carried out according to the instructions of the manufacturer. Experimental methods and protein level scoring criteria can be found in our previous study [12].…”

Section: Collection Of Samples and Performance Of Immunohistochemistrymentioning

confidence: 99%

“…All mRNA expression-associated data were transformed by log 2 (x + 1). Datasets with the same platform (e.g., GSE32036 and GSE4127 from GPL6884) were merged for a combined dataset after eliminating batch effects [13][14][15][16], which was similar to the published study [12].…”

Section: Data Standardization and Elimination Of Batch Effects Betwee...mentioning

confidence: 99%

The clinical significance of integrin subunit alpha V in cancers: from small cell lung carcinoma to pan-cancer

Tang

et al. 2022

BMC Pulm Med

Self Cite

View full text Add to dashboard Cite

Background Little is known about the relationship between integrin subunit alpha V (ITGAV) and cancers, including small cell lung cancer (SCLC). Methods Using large sample size from multiple sources, the clinical roles of ITGAV expression in SCLC were explored using differential expression analysis, receiver operating characteristic curves, Kaplan–Meier curves, etc. Results Decreased mRNA (SMD = − 1.05) and increased protein levels of ITGAV were detected in SCLC (n = 865). Transcription factors—ZEB2, IK2F1, and EGR2—may regulate ITGAV expression in SCLC, as they had ChIP-Seq (chromatin immunoprecipitation followed by sequencing) peaks upstream of the transcription start site of ITGAV. ITGAV expression made it feasible to distinguish SCLC from non-SCLC (AUC = 0.88, sensitivity = 0.78, specificity = 0.84), and represented a risk role in the prognosis of SCLC (p < 0.05). ITGAV may play a role in cancers by influencing several immunity-related signaling pathways and immune cells. Further, the extensive pan-cancer analysis verified the differential expression of ITGAV and its clinical significance in multiple cancers. Conclusion ITGAV served as a potential marker for prognosis and identification of cancers including SCLC.

show abstract

Upregulation of BIRC5 plays essential role in esophageal squamous cell carcinoma

Cited by 4 publications

References 42 publications

Ogt Demonstrated Conspicuous Clinical Significance in Cancers, from Pan-Cancer to Small-Cell Lung Cancer

Ogt Demonstrated Conspicuous Clinical Significance in Cancers, from Pan-Cancer to Small-Cell Lung Cancer

BIRC5 expression correlated with immunosuppressive phenotype and predicted inferior response to immunotherapy in lung adenocarcinoma

The clinical significance of integrin subunit alpha V in cancers: from small cell lung carcinoma to pan-cancer

Contact Info

Product

Resources

About